Vasagatan 43A, Box 53245
400 16 Göteborg
Sweden
Tele: +46 (0)31-49 49 25
Fax: +46 (0)31-47 49 72
E-mail: info@pharmacure.com
Frequently asked questions
Q: Nozovent Classic is made of plastic. Unsuitable plastics that come into contact with human tissue can discharge softening agents. What about the plastic in Nozovent? Does it discharge any substances? Can it cause allergies?
A: The plastic that is used to produce Nozovent is called Pebax ® 2533 SN 01 Polyether Block Amide. It has been specially selected for medical use, which means that it does not contain softening agents. Nozovent is inert – in other words, it displays no tendency to release molecules. The plastic in Nozovent does not cause allergies.
Q: Why isn’t Nozovent coloured to make it easier to find if you happen to drop it?
A: Dyes in plastic can cause allergies. Pharmacure Health Care AB is not planning to dye the plastic in Nozovent. People can, however, colour the central section with a marker pen to make Nozovent easier to find, if they drop it in bed or in the garden, for example.
Q: Is there any risk that Nozovent Classic will come away during sleep and accompany the inhaled air into the nose and down into the lungs?
A: No, it would never get that far! Nozovent Classic is unable to pass through a narrow nostril without the wearer waking up. If this were theoretically possible, the next blocking action – the vomiting reflex – would take effect.
Q: Nozovent products improve nasal breathing. Is it known by how many per cent the volume of the inhaled air increases?
A: The breathing improvement effect of Nozovent is experienced every day by hundreds of thousands of users all over the world. This effect has also been studied scientifically by people including Professor Björn Petruson, ENT Clinic, Sahlgrenska University Hospital, Göteborg, Sweden. He has written a review article of various studies entitled The importance of improved nasal breathing: a review of the Nozovent nostril dilator, which was published in the medical journal Acta Oto-Laryngologica in 2007. In this article, Björn Petruson presents the effects of dilating the nostrils using Nozovent Classic. In one study, the air flow during inspiration increased by 29 per cent. In another, it rose by between 5.5 and 45 per cent – large individual variations, in other words. Patients with pulmonary diseases, such as chronic asthma or COPD, can expect only slight or no improvement from using Nozovent products. No corresponding studies have been conducted on the Nozovent Nasal Strip, but the effects can be expected to be the same.
